Gain Therapeutics, Inc. (GANX) News

Gain Therapeutics, Inc. (GANX): $1.73

0.07 (-3.89%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add GANX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#148 of 306

in industry

Filter GANX News Items

GANX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GANX News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest GANX News From Around the Web

Below are the latest news stories about GAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GANX as an investment opportunity.

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board (CAB) to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial

Yahoo | January 8, 2025

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company’s Chief Financial Officer since

Yahoo | January 7, 2025

Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM

Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics (GANX) after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson’s disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try No

Yahoo | December 25, 2024

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson’s disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GA

Yahoo | December 23, 2024

Gain Therapeutics To Present At Biotech Showcase 2025

Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Financial Officer and Interim Chief Executive Officer of Gain, will give a corporate presentation at Biotech Showcase

Yahoo | December 11, 2024

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. “The third quarter of 2024 marked substantial pro

Yahoo | November 14, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors BETHESDA, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therap

Yahoo | October 23, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be presented at the 36th EORTC-NCI-AACR (ENA) Symposium on molecular targets and

Yahoo | October 15, 2024

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will give an oral presentation on the Company’s clinical stage lead drug candidate GT-02287 at the Michael J. Fox Foundation’s (MJFF) 16th Annual Parkinson’s Dise

Yahoo | October 9, 2024

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric

Yahoo | October 7, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!